Treatment of Active CLL with Mutated IGHV Status Without TP53 Mutation in a Medically Fit Patient
This page addresses the evidence-based treatment approach for a molecularly defined subgroup of chronic lymphocytic leukemia: active disease with confirmed mutated IGHV status, absence of TP53 mutation, and absence of del(17p), in a patient who is medically fit.
The clinical scenario requires confirmation of three key features before therapy selection: active CLL requiring treatment, mutated IGHV status, and the absence of both TP53 mutation and del(17p) chromosomal deletion.
Medical fitness is assessed alongside these molecular markers, as fitness status directly shapes which therapeutic options are appropriate for this population.
Treatment Approach
For this molecularly defined population, the approach at relapse centres on selecting from targeted therapy options — evidence supports both time-limited and continuous treatment strategies, with the choice informed by prior treatment history and the duration of the preceding response. The full decision algorithm, agent selection, and sequencing criteria are detailed in the complete protocol.
References
- CLL with mutated IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies):
- Fit patients: CIT according to age (FCR or BR) or ibrutinib [I, A]. Venetoclax plus obinutuzumab might be an alternative to BTKis, but data for fit patients are still pending [III, A].
- One of the two following treatment options should be chosen [I, A]:
- Venetoclax plus rituximab for 24 months;
- Ibrutinib or acalabrutinib or other BTKis (if available) as continuous therapy.
- The PI3K inhibitor idelalisib in combination with rituximab [II, B];
- In case of long-lasting remissions (>3 years) to prior time-limited therapy, patients may be re-exposed to the same treatment regimen, though data are limited with no long-term observation [II, B].
View source ↗